×
About 30,488 results

ALLMedicine™ B-cell Lymphoma Center

Research & Reviews  14,495 results

The spleen as a sanctuary site for residual leukemic cells following ABT-199 monotherap...
https://doi.org/10.1182/bloodadvances.2021004177
Blood Advances; Di Grande A, Peirs S et. al.

Apr 8th, 2021 - B-cell lymphoma 2 (BCL-2) has recently emerged as a therapeutic target for early T-cell progenitor acute lymphoblastic leukemia (ETP-ALL), a high-risk subtype of human T-cell ALL. The major clinical challenge with targeted therapeutics, such as th...

Factors for the optimal selection of granulocyte colony-stimulating factor preparations...
https://doi.org/10.1186/s12885-021-08068-0 10.1016/j.critrevonc.2017.11.005 10.1016/j.critrevonc.2010.02.002 10.1002/cncr.21847 10.3109/10428194.2015.1045894 10.1200/JCO.2006.08.8823 10.6004/jnccn.2005.0031 10.1200/JCO.2005.05.645 10.1186/1471-2407-11-404 10.1007/s10549-018-4837-4 10.1007/s12032-016-0850-9 10.1007/s00520-011-1241-6
BMC Cancer; Yokoyama M, Kusano Y et. al.

Apr 7th, 2021 - A classification tree was used to analyze background factors for granulocyte colony-stimulating factor (G-CSF) preparation selection for febrile neutropenia (FN) prophylaxis in Japanese patients with non-Hodgkin B-cell lymphoma receiving the first...

The bidirectional increased risk of B-cell lymphoma and T-cell lymphoma.
https://doi.org/10.1182/blood.2020010497
Blood Chihara D, Dores G et. al.

Apr 6th, 2021 - Lymphoma survivors have a significantly higher risk of developing second primary lymphoma than the general population; however, bidirectional risks of developing B- and T-cell lymphomas (BCL; TCL) specifically are less well understood. We used pop...

Evaluation of mid-term (6-12 months) neurotoxicity in B-cell lymphoma patients treated ...
https://doi.org/10.1093/neuonc/noab077
Neuro-oncology Maillet D, Belin C et. al.

Apr 6th, 2021 - CAR T-cells are profoundly changing the standard of care in B-cell malignancies. This new therapeutic class induces a significant number of acute neurotoxicity, but data regarding mid and long-term neurological safety are scarce. We evaluated mid-...

see more →

Guidelines  57 results

Diffuse Large B-Cell Lymphoma’s New Genomics: The Bridge and the Chasm
https://ascopubs.org/doi/full/10.1200/JCO.20.01501
Journal of Clinical Oncology; Crombie JL

Aug 19th, 2020 - We briefly describe the new genomic categories, highlighting both their potential to profoundly transform the approach to DLBCL treatment and the significant challenges this will entail.

Retreatment with CAR-T therapy shows clinical efficacy in lymphoma
https://www.healio.com/news/hematology-oncology/20200708/retreatment-with-cart-therapy-shows-clinical-efficacy-in-lymphoma

Jul 7th, 2020 - In a small sample, retreatment of patients with large B-cell lymphoma showed good response, notably in patients who had complete response on initial treatment, according to a poster presented at ASCO 2020 Virtual Scientific Program.

Novel CAR-T Cell Therapy Combination Shows Preliminary Activity in R/R B-cell Lymphoma
https://www.targetedonc.com/view/novel-car-t-cell-therapy-combination-shows-preliminary-activity-in-r-r-b-cell-lymphoma

May 28th, 2020 - First-in-human findings show that ALLO-501, an allogeneic chimeric antigen receptor (CAR)-T cell therapy plus ALLO-647, a monoclonal antibody, has clinical activity and is tolerable in patients with relapsed/refractory large B-cell or follicular l...

Covid-19 infection in therapy-naive patients with B-cell chronic lymphocytic leukemia
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7192083/
Leukemia Research; Paneesha S

Apr 29th, 2020 - The global pandemic of the novel coronavirus SARS-CoV-2 represents one of the greatest infectious challenges to human health in recent history. At the current time over 3.2 million people have been infected and this has proved fatal in over 230,00...

The effect of COVID-19 on the management of patients with lymphoma
https://lymphomahub.com/medical-information/the-effect-of-covid-19-on-the-management-of-patients-with-lymphoma
Lymphoma Hub;

Mar 23rd, 2020 - The whole medical community is living in an extraordinary and unexpected time, facing the SARS-CoV-2 pandemic. Every medical specialty is currently defining measures and guidelines to manage the risk of infection among patients and during therapy ...

see more →

Drugs  17 results see all →

Clinicaltrials.gov  15,139 results

The spleen as a sanctuary site for residual leukemic cells following ABT-199 monotherap...
https://doi.org/10.1182/bloodadvances.2021004177
Blood Advances; Di Grande A, Peirs S et. al.

Apr 8th, 2021 - B-cell lymphoma 2 (BCL-2) has recently emerged as a therapeutic target for early T-cell progenitor acute lymphoblastic leukemia (ETP-ALL), a high-risk subtype of human T-cell ALL. The major clinical challenge with targeted therapeutics, such as th...

Factors for the optimal selection of granulocyte colony-stimulating factor preparations...
https://doi.org/10.1186/s12885-021-08068-0 10.1016/j.critrevonc.2017.11.005 10.1016/j.critrevonc.2010.02.002 10.1002/cncr.21847 10.3109/10428194.2015.1045894 10.1200/JCO.2006.08.8823 10.6004/jnccn.2005.0031 10.1200/JCO.2005.05.645 10.1186/1471-2407-11-404 10.1007/s10549-018-4837-4 10.1007/s12032-016-0850-9 10.1007/s00520-011-1241-6
BMC Cancer; Yokoyama M, Kusano Y et. al.

Apr 7th, 2021 - A classification tree was used to analyze background factors for granulocyte colony-stimulating factor (G-CSF) preparation selection for febrile neutropenia (FN) prophylaxis in Japanese patients with non-Hodgkin B-cell lymphoma receiving the first...

The bidirectional increased risk of B-cell lymphoma and T-cell lymphoma.
https://doi.org/10.1182/blood.2020010497
Blood Chihara D, Dores G et. al.

Apr 6th, 2021 - Lymphoma survivors have a significantly higher risk of developing second primary lymphoma than the general population; however, bidirectional risks of developing B- and T-cell lymphomas (BCL; TCL) specifically are less well understood. We used pop...

Evaluation of mid-term (6-12 months) neurotoxicity in B-cell lymphoma patients treated ...
https://doi.org/10.1093/neuonc/noab077
Neuro-oncology Maillet D, Belin C et. al.

Apr 6th, 2021 - CAR T-cells are profoundly changing the standard of care in B-cell malignancies. This new therapeutic class induces a significant number of acute neurotoxicity, but data regarding mid and long-term neurological safety are scarce. We evaluated mid-...

see more →

News  775 results

Clear Benefit of Blinatumomab in Kids With Relapsed B-Cell Lymphoma
https://www.medscape.com/viewarticle/946711

Mar 2nd, 2021 - NEW YORK (Reuters Health) - Two randomized trials show a clear benefit of blinatumomab in combination with conventional chemotherapy in children with high-risk relapsed B-cell acute lymphoblastic leukemia (B-ALL), with improved outcomes and a favo...

FDA OKs New CAR T- Cell Tx for Large B-cell Lymphomas
https://www.medscape.com/viewarticle/945417

Feb 4th, 2021 - The US Food and Drug Administration (FDA) has approved lisocabtagene maraleucel (Breyanzi), a chimeric antigen receptor (CAR) T-cell product for the treatment of adults with certain types of relapsed or refractory large B-cell lymphoma who relapse...

First Data for CAR T-cell Therapy in Follicular Lymphoma: ZUMA-5
https://www.medscape.com/viewarticle/942494

Dec 10th, 2020 - For the first time, a chimeric antigen receptor (CAR) therapy has yielded a high response rate among patients with relapsed/refractory indolent non-Hodgkin lymphoma (iNHL), including patients with follicular lymphoma (FL) and marginal zone lymphom...

B-cell Lymphoma Might Respond to N-myristoyltransferase Inhibition
https://www.medscape.com/viewarticle/941669

Nov 26th, 2020 - NEW YORK (Reuters Health) - Targeting N-myristoylation might prove to be an effective treatment for B-cell lymphoma and other cancers, according to a preclinical study. Myristoylation, the N-terminal modification of proteins mediated by N-myristoy...

CAR T for All R/R DLBCL Patients: The Jury Is Still Out
https://www.medscape.com/viewarticle/939947

Oct 27th, 2020 - Is it time to consider chimeric antigen receptor (CAR) T-cell therapy for all relapsed/refractory diffuse large B-cell lymphoma patients? Maybe not, according to Andrew Zelenetz, MD, PhD. CAR T-cell therapy has demonstrated activity in relapsed/re...

see more →

Patient Education  5 results see all →